TD Cowen Adjusts Price Target on Revvity to $175 From $130

JPMorgan raised its price target for Revvity from $110 to $155. TD Cowen also increased its target to $175 from $130. Revvity's stock has risen 60.29% year-to-date, trading at $155.08 at the time of the report.

Several biotech stocks hit 52-week highs on September 24, 2026. CareDx (CDNA) rose 13% to $63.09, Grail (GRAL) climbed 15% to $126.81, Adaptive Biotechnologies (ADPT) gained 6% to $29.58, Revvity (RVTY) increased 6% to $152.26, and Twist Bioscience (TWST) surged 16% to $185.22. Key catalysts included regulatory milestones, clinical trial results, and strategic acquisitions.

Revvity Inc. (NYSE:RVTY) announced an agreement to acquire France-based Human Cell Design, expanding its portfolio for diabetes and obesity research. The deal, expected to close in Q4 2026, adds Human Cell Design's pancreatic beta cell models to Revvity's Life Sciences offerings. Revvity ended Q2 2026 with $1.02 billion in cash. Shares were down 0.27% premarket.

UBS downgraded Revvity to Neutral from Buy and raised its price target to $140 from $120. The company recently acquired Human Cell Design SAS and presented at the Wells Fargo Healthcare Conference. Revvity's stock is currently trading at $123.85, with a 5-day change of -2.54% and a year-to-date change of +28.01%.

Revvity (NYSE: RVTY) will acquire Human Cell Design (HCD), a biotech firm specializing in human cell models for metabolic diseases. The deal, expected to close in Q4 2026, will add HCD's pancreatic beta cell models to Revvity's life sciences portfolio, supporting drug discovery and preclinical research. The acquisition aims to enhance Revvity's capabilities in metabolic disease therapies, including GLP-1 and GPCR-targeting treatments. Financial terms were not disclosed.

Revvity agreed to acquire Human Cell Design, a France-based company specializing in human pancreatic beta cell models and preclinical research tools for metabolic disease drug discovery. The deal, expected to close in Q4 2026, will expand Revvity's Life Sciences portfolio, enhancing its capabilities in diabetes and obesity research. Financial terms were not disclosed. Revvity reported $2.9 billion in 2025 revenue.